Lofarma S.p.A. is a pharmaceutical company involved in the diagnosis and treatment of allergic respiratory diseases. The company provides immunotherapy for allergies and diagnostic testing, along with products for allergy prevention and treatment. Lofarma serves the healthcare sector with a focus on allergy management. It is based in Italy.

Vaxent has developed a StepNovA vaccine for Group A streptococcus

FluGen, Inc. is a clinical-stage vaccine company focused on developing vaccines for influenza and respiratory diseases. The company offers the M2SR Vaccine Platform, which is designed to provide efficacy against annual flu variations by stimulating a broad immune response at the site of infection. FluGen's vaccines aim to address needs in flu prevention, including protection against drifted strains. It was founded in 2007 and is based in Madison, Wisconsin.

Vivaldi Biosciences focuses on the development of vaccines for viral respiratory diseases, operating in the biotechnology and healthcare sectors. The company's main offerings include the development of vaccines that provide protection against epidemic and pandemic viral respiratory diseases, utilizing a technology platform known as Delta NS1. Its vaccines, administered via nasal spray, are designed to rapidly induce interferon, generating protection against viruses entering the nasal passages and activating systemic antibody and cell-based protective immunity. It was founded in 2006 and is based in Fort Collins, Colorado.

ModiQuest is a biotechnology company focused on developing novel therapeutics for inflammatory diseases, particularly in the domain of rheumatoid arthritis. The company specializes in using recombinant antibody technology to create therapeutic leads aimed at treating rheumatoid arthritis and other inflammatory conditions. ModiQuest primarily serves the biopharmaceutical industry with its therapeutic leads designed for co-development or outlicensing. It was founded in 2004 and is based in Netherlands.

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology.  The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University.  Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com